Jodas Expoim Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Jodas Expoim Private Limited Pharmaceutical Export Portfolio Dataset — 33 Products, $24.4M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Jodas Expoim Private Limited — Pharmaceutical Exporter Profile (2026) | 33 Products, $24.4M Trade | TransData Nexus

Product Portfolio — Top 30 by Export Value

Jodas Expoim Private Limited exports 33 pharmaceutical products across 8 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Paclitaxel	Oncology	$3.1M	63	3.8%	4
2	Imatinib	Advanced Oncology	$1.9M	38	6.5%	4
3	Capecitabine	Advanced Oncology	$1.9M	37	2.1%	6
4	Oxaliplatin	Advanced Oncology	$1.8M	36	3.4%	2
5	Gemcitabine	Oncology	$1.8M	35	3.8%	7
6	Temozolomide	Advanced Oncology	$1.8M	35	7.4%	3
7	Anastrozole	Advanced Oncology	$1.2M	24	1.1%	6
8	Heparin	Cardiovascular	$1.1M	23	0.3%	8
9	Syringe	Medical Devices & Diagnostics	$1.0M	20	0.6%	6
10	Ertapenem	Advanced Antibiotics	$850.0K	17	0.8%	2
11	Acyclovir	Antivirals	$750.0K	15	0.6%	9
12	Docetaxel	Oncology	$700.0K	14	1.8%	5
13	Irinotecan	Oncology	$600.0K	12	1.5%	7
14	Nilotinib	Advanced Oncology	$600.0K	12	48.2%	1
15	Fulvestrant	Advanced Oncology	$550.0K	11	3.8%	2
16	Amphotericin	Antifungals	$500.0K	10	0.6%	4
17	Sulfamethoxazole	Advanced Antibiotics	$481.8K	21	2.4%	8
18	Trimethoprim	Advanced Antibiotics	$481.8K	21	1.8%	12
19	Carboplatin	Oncology	$475.9K	11	0.7%	15
20	Sunitinib	Advanced Oncology	$454.0K	19	0.7%	6
21	Tobramycin	Antibiotics	$450.0K	9	1.1%	9
22	Gefitinib	Advanced Oncology	$395.7K	11	5.8%	3
23	Thalidomide	Advanced Oncology	$257.8K	12	13.3%	3
24	Pemetrexed	Advanced Oncology	$250.0K	5	0.9%	3
25	Teicoplanin	Advanced Antibiotics	$250.0K	5	4.0%	3
26	Melphalan	Advanced Oncology	$150.6K	5	1.2%	7
27	Imipenem	Advanced Antibiotics	$150.0K	3	0.4%	8
28	Linezolid	Advanced Antibiotics	$150.0K	3	0.4%	7
29	Exemestane	Advanced Oncology	$136.6K	6	0.9%	10
30	Dasatinib	Advanced Oncology	$71.8K	3	0.4%	12

Jodas Expoim Private Limited exports 33 pharmaceutical products across 8 therapeutic categories with a total export value of $24.4M. The company is the #1 Indian exporter in 1 product: Nilotinib. The top category is Advanced Oncology (47.1% of portfolio), followed by Oncology (27.4%), reflecting a diversified portfolio where the top 5 products account for only 42.9% of total value.

Showing top 30 of 33 products. Contact us for complete data.

Jodas Expoim Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

Jodas Expoim Private Limited, established on September 4, 2006, is a private pharmaceutical company headquartered in Mulugu, Telangana, India. The company is registered under the Corporate Identification Number (CIN) U21001TG2006PTC110218. As of March 31, 2024, Jodas Expoim reported an authorized capital of ₹115.50 crore and a paid-up capital of ₹113.17 crore. The company employs approximately 737 professionals. Its manufacturing facility is located at Plot No.55 and 45, APIIC, Biotech Phase III, Karkapatla, Mulugu, Telangana, 502279.

2Manufacturing Facilities

Jodas Expoim operates a manufacturing plant situated in Mulugu, Telangana, India. The facility specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. While specific production capacities are not publicly disclosed, the plant is designed to meet both domestic and international demand, adhering to stringent quality standards. The company's focus on oncology, contrast media, and critical care products underscores its commitment to specialized therapeutic areas.

3Key Leadership

The leadership team at Jodas Expoim Private Limited comprises:

Satyendra Kumar Singh: Co-Founder and Managing Director, appointed on May 8, 2012.

Jyoti Loomba: Co-Founder and Chief Managing Director, appointed on September 4, 2006.

Shashi Shanker Parsad Singh: Co-Founder and Managing Director, appointed on November 29, 2008.

Piyush Kumar Gupta: Director, appointed on January 11, 2012.

This team brings extensive experience in pharmaceutical manufacturing and international business development.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Jodas Expoim Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Jodas Expoim Private Limited has made significant strides in regulated markets, particularly in the United States, European Union, United Kingdom, Australia, and Japan. The company has successfully filed Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA), leading to the approval of several generic formulations. In the EU and UK, Jodas Expoim has obtained marketing authorizations for its products, ensuring compliance with the European Medicines Agency (EMA) and Medicines and Healthcare products Regulatory Agency (MHRA) standards. The company's adherence to Good Manufacturing Practice (GMP) guidelines has facilitated market access in Australia and Japan, where it has established distribution partnerships. These regulatory approvals underscore Jodas Expoim's commitment to quality and its capability to meet the stringent requirements of developed markets.

2Emerging Markets

Jodas Expoim Private Limited has strategically expanded its presence in emerging markets across Africa, Latin America, and Southeast Asia. The company's products are registered in over 40 countries, facilitated by the World Health Organization (WHO) prequalification, which has been instrumental in gaining access to these regions. By collaborating with local partners, Jodas Expoim has established robust distribution networks, ensuring the availability of its high-quality medicines in underserved markets. This expansion aligns with the company's mission to make life-saving generics and biopharmaceutical products accessible globally.

Jodas Expoim Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Jodas Expoim Private Limited has achieved notable milestones with the U.S. Food and Drug Administration (FDA). The company has registered its manufacturing facility with the FDA, ensuring compliance with U.S. regulatory standards. It has successfully filed multiple Abbreviated New Drug Applications (ANDAs), leading to the approval of several generic formulations. These approvals reflect the company's commitment to quality and its capability to meet the stringent requirements of the U.S. market. Additionally, Jodas Expoim has maintained a clean inspection history, with no Form 483 observations or warning letters issued by the FDA, indicating consistent adherence to Good Manufacturing Practice (GMP) standards.

2WHO & EU GMP

Jodas Expoim Private Limited has obtained Good Manufacturing Practice (GMP) certifications from both the World Health Organization (WHO) and the European Union (EU). The WHO prequalification has been instrumental in facilitating the company's entry into various international markets, particularly in Africa, Latin America, and Southeast Asia. The EU GMP certification underscores the company's adherence to high-quality manufacturing standards, enabling it to supply products to European markets. These certifications reflect Jodas Expoim's commitment to maintaining stringent quality controls and its capability to meet international regulatory requirements.

Jodas Expoim Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Jodas Expoim Private Limited operates in a competitive landscape, with several key players in the pharmaceutical industry offering similar products. In the oncology segment, companies such as Dr. Reddy's Laboratories, Cipla, and Sun Pharmaceutical Industries are prominent competitors. Jodas Expoim's focus on specialized formulations, including contrast media and critical care products, differentiates it from competitors who may have a broader product portfolio. The company's adherence to international quality standards, as evidenced by its WHO prequalification and EU GMP certifications, positions it favorably in the market. However, the competitive dynamics are influenced by factors such as pricing strategies, regulatory approvals, and market access, which can impact Jodas Expoim's market share and growth prospects.

2Key Differentiators

Jodas Expoim Private Limited distinguishes itself through its specialized focus on oncology, contrast media, and critical care products. The company's commitment to innovation and continuous research and development enables it to offer high-quality generics and biopharmaceuticals. Its adherence to stringent quality standards, as demonstrated by certifications from the WHO and EU GMP, ensures the reliability and safety of its products. Additionally, Jodas Expoim's strategic expansion into emerging markets, facilitated by WHO prequalification, enhances its global reach and accessibility. These differentiators contribute to the company's competitive edge in the pharmaceutical industry.

Buyer Due Diligence Brief — Evaluating Jodas Expoim Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Jodas Expoim Private Limited has demonstrated a strong track record in pharmaceutical manufacturing, with a focus on oncology, contrast media, and critical care products. The company's export volume of $24.4 million USD across 552 shipments indicates a consistent and reliable supply chain. Its adherence to international quality standards, as evidenced by certifications from the WHO and EU GMP, underscores the company's commitment to product excellence

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Jodas Expoim Private Limited

How many pharmaceutical products does Jodas Expoim Private Limited export from India?

Jodas Expoim Private Limited exports 33 pharmaceutical products across 8 therapeutic categories. The top exports are Paclitaxel ($3.1M), Imatinib ($1.9M), Capecitabine ($1.9M), Oxaliplatin ($1.8M), Gemcitabine ($1.8M). Total export value is $24.4M.

What is Jodas Expoim Private Limited's total pharmaceutical export value?

Jodas Expoim Private Limited's total pharmaceutical export value is $24.4M, based on 552 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Jodas Expoim Private Limited the #1 Indian exporter?

Jodas Expoim Private Limited is the #1 Indian exporter in 1 products: Nilotinib (48.2% market share).

What therapeutic categories does Jodas Expoim Private Limited cover?

Jodas Expoim Private Limited exports across 8 therapeutic categories. The largest are Advanced Oncology (47.1%, 17 products), Oncology (27.4%, 5 products), Advanced Antibiotics (9.7%, 6 products).

Get Full Jodas Expoim Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.

Jodas Expoim Private Limited

Jodas Expoim Private Limited — Export Portfolio & Destination Treemap

Who is Jodas Expoim Private Limited? — Company Overview & Market Position

What Does Jodas Expoim Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

Jodas Expoim Private Limited Therapeutic Categories — 8 Specializations